PharmaEssentia has signed a significant licence agreement with WuXi Biologics, securing exclusive global rights for the research, development, manufacturing, and commercialisation of a promising myeloid immune checkpoint antibody candidate.
This agreement involves several financial components, including an initial payment upon signing, future payments linked to research and development milestones, regulatory achievements, and sales milestones, as well as ongoing sales royalties.
This collaboration with WuXi Biologics strongly supports its dedication to expediting priority development programmes in the fields of oncology, haematology, and immunology. The primary goal is to swiftly advance this specific antibody candidate, which holds tremendous potential as a groundbreaking scientific breakthrough.
This agreement underscores PharmaEssentia's commitment in the rapid advancement of this specific candidate, which carries the potential to harness a revolutionary scientific breakthrough in order to create a treatment that can significantly ease the substantial medical burdens faced by patients battling solid tumours.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!